Related news: https://reurl.cc/Rdgxln
Our company has successively acquired patents for a diabetes glucagon mitigation system in Australia, EU, Canada, Russia and South Korea. We are also applying for patents in other countries around the globe.
After 7 years of hard work and perseverance, our proprietary non-invasive, electroceutical technology for treating and alleviating symptoms associated with type 2 diabetes has been approved by MOEA for R&D subsidies.
Our randomized, double-blind trial is underway at National Taiwan University Hospital, National Cheng Kung University Hospital, and two other medical facilities. Under the investigative leadership of 20 medical professionals, the study is expected to be completed in 2018 and potentially become the world’s first non-invasive electronic medical device used to alleviate symptoms associated with type 2 diabetes.
In mid-2016, we officially acquired the US patent for diabetes glucagon mitigation using an electrical energy wave generator, and have begun patent applications for this technology in 12 other countries. In addition, TRWR has obtained 11 patents in the field of electroceutical technology development around the world.